Cholestyramine
Progressive Familial Intrahepatic Cholestasis
AlbireoOtherPhase 1Dormant
CC
47/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 32/ 100
- Competitive Position
- 95/ 100
Competitive context
1 Active assets in the Progressive Familial Intrahepatic Cholestasis cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Maralixibat Mirum Pharmaceuticals, Inc. | Phase 2 | B |
Odevixibat Albireo | Phase 1 | CCC |
Questran Albireo | Phase 1 | CC |
[14c]-a4250 Albireo | Phase 1 | CC |
Same molecule, other indications
Cholestyramine is also rated in:
metabolic dysfunction-associated steatotic liver diseaseDormant
B
Indicative · Phase 2
57 / 100
View asset →Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →